XML 39 R22.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2025

During the quarter ended March 31, 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated trading plans intended to satisfy Rule 10b5-1(c), except as set forth in the following table:

Name

Title

Adoption or Termination Date

Plan Start Date

Plan End Date

Vesting and

Subject to

Sell-To-

Cover (1)

Other
Shares
Being Sold
(Subject to
Certain
Conditions)

Ken Myszkowski

Chief Financial Officer

Terminated on 1/6/2025

6/11/2024

2/28/2025

n/a

115,000

Ken Myszkowski

Chief Financial Officer

1/7/2025

4/10/2025

12/31/2025

n/a

170,599

James Hamilton

Chief Medical Officer, Head of R&D

2/24/2025

5/28/2025

11/30/2026

n/a

60,000

Christopher Anzalone

Chief Executive Officer

Terminated on 3/12/2025

12/4/2024

12/31/2026

2,082,892

n/a

(1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.

Non-Rule 10b5-1 Arrangement Adopted

false

Non-Rule 10b5-1 Arrangement Terminated

false

James Hamilton [Member]

Trading Arrangements, by Individual

Name

James Hamilton

Title

Chief Medical Officer, Head of R&D

Rule 10b5-1 Arrangement Adopted

true